Alan David, DO
Neuromusculoskeletal Medicine & OMM · White Plains, NYNPI 1740240613
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Eisai Inc. at 41.1% of the total. 2025 is the largest year on record at $458, more than ten times the $13 reported in 2020.
Across 29 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$300
- Boston Scientific$81
- Biogen$64
- Pfizer$63
- Amgen$46
- AbbVie$46
- plus $129 from 6 others
What the payments were for
- Food & beverage$730100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 11 | $300 |
| Boston Scientific | 2 | $81 |
| Biogen | 3 | $64 |
| Pfizer | 3 | $63 |
| Amgen | 2 | $46 |
| AbbVie | 2 | $46 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Avion Pharmaceuticals | 1 | $22 |
| Nevro Corp. | 1 | $20 |
| SK Life Science, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$730 in reported general payments places this provider in the 80th percentile of 46 neuromusculoskeletal medicine & omm providers in New York.
See all neuromusculoskeletal medicine & omm providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 37 | $8,766 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 192 | $3,594 |
| Carbamazepine ErCarbamazepine | 19 | $3,202 |
| Duloxetine Hcl | 169 | $3,058 |
| Tacrolimus | 11 | $2,789 |
| Lamotrigine ErLamotrigine | 31 | $2,031 |
| Donepezil Hcl | 155 | $1,952 |
| Memantine Hcl | 65 | $1,903 |
| Levetiracetam | 58 | $1,584 |
| AmantadineAmantadine Hcl | 22 | $1,086 |
| Risperidone | 58 | $854 |
| Mirtazapine | 42 | $580 |
| Celecoxib | 72 | $521 |
| Gabapentin | 117 | $472 |
| Escitalopram Oxalate | 76 | $426 |
Paid to pharmacies, not to this prescriber.
Other neuromusculoskeletal medicine & omm in White Plains
- Barry JordanWhite Plains$231
- Mary Beth WalshWhite Plains$15
- Mehri SonghorianElmhurst$8K
- Clair CascellaNew Hyde Park$5K
- Richard ChmielewskiNew Hartford$3K
- Brian WaldronNew York$2K
- Kerin HausknechtLynbrook$2K
- Mohammed IslamElmhurst$1K
- Michael FlorekNew York$1K
- Patricia HartKirkville$936
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.